InspireMD: Osiris buys 307,693 shares with warrants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InspireMD, Inc. director Paul Stuka reported that Osiris Investment Partners, L.P. purchased 307,693 common shares and 230,769 accompanying Series L common stock warrants in the company's underwritten public offering on November 13, 2026. The stated combined public offering price was $0.65 per share of common stock and accompanying warrants.
After the reported purchases, Osiris was reported to hold 731,397 common shares and 230,769 warrants. Stuka is managing member of Osiris's general partner and disclaims beneficial ownership except to the extent of his pecuniary interest. The warrants are immediately exercisable at $0.65 per share and expire November 16, 2027. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series L Common Stock Warrant F4, F2 | 230,769 | $0.00 | $0.00 |
| Purchase | Common Stock F1, F2 | 307,693 | $0.65 | $200K |
| Holding | Common Stock F3 | -- | -- | -- |
Footnotes (4)
- F1. Represents shares of common stock purchased by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris") in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
- F2. These securities are held by Osiris. The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
- F3. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
- F4. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
Key Figures
Key Terms
underwritten public offering financial
Series L common stock warrants technical
pecuniary interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the exercise terms for Osiris's NSPR warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.